Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Specialized pro-resolving mediators (SPMs) are bioactive lipid molecules derived from omega-3 and omega-6 fatty acids that play a role in actively resolving inflammation. There is growing scientific interest in the use of SPMs for inflammatory conditions like Crohn's Disease, a type of inflammatory bowel disease (IBD). Preclinical studies in animal models of colitis suggest that SPMs, such as resolvins, protectins, and maresins, can reduce inflammatory cell infiltration, promote tissue repair, and restore intestinal barrier function. These findings indicate a potential therapeutic benefit in modulating the chronic inflammation seen in Crohn's Disease.

However, direct evidence in humans with Crohn's Disease is limited. Most research to date has focused on laboratory and animal studies, with only a few small pilot clinical trials investigating SPMs in IBD patients more broadly. These early-phase trials have shown signals of safety and potential efficacy, but results are preliminary and cannot yet support widespread clinical use. Reviews of the literature emphasize the need for larger, well-designed human trials to determine the efficacy, optimal formulation, and dosing of SPMs in Crohn’s Disease.

In summary, while there is a scientific rationale and early-stage preclinical evidence supporting the use of SPMs for Crohn's Disease, robust clinical validation is currently lacking. The evidence base is therefore rated at 2 out of 5, reflecting promising but still preliminary support for SPMs in this context.

More about specialized pro-resolving mediators (SPMs)
More about Crohn's Disease

Other ingredients used for Crohn's Disease

Other health conditions supported by specialized pro-resolving mediators (SPMs)

Products containing specialized pro-resolving mediators (SPMs)

Douglas Laboratories QÜELL® FISH OIL DHA Ultra SPM